Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carmen Blanco-Aparicio

Showing results (1-10 of 70) with videos related to

Pageof 7
Sort By:
Biochemical Pharmacology|October 9, 2012
Pim kinases in cancer: diagnostic, prognostic and treatment opportunitiesCarmen Blanco-Aparicio, Amancio Carnero
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|October 23, 2008
Genetic modelling of the PTEN/AKT pathway in cancer researchOliver Renner, Carmen Blanco-Aparicio, Amancio Carnero
Medicinal Research Reviews|April 12, 2013
The PIM family of serine/threonine kinases in cancerMaja Narlik-Grassow, Carmen Blanco-Aparicio, Amancio Carnero
The Journal of Biological Chemistry|November 17, 2001
Two clusters of residues at the docking groove of mitogen-activated protein kinases differentially mediate their functional interaction with the tyrosine phosphatases PTP-SL and STEPCéline Tárrega, Carmen Blanco-Aparicio, Juan José Muñoz, et al.
The Biochemical Journal|February 14, 2003
Differential interaction of the tyrosine phosphatases PTP-SL, STEP and HePTP with the mitogen-activated protein kinases ERK1/2 and p38alpha is determined by a kinase specificity sequence and influenced by reducing agentsJuan José Muñoz, Céline Tárrega, Carmen Blanco-Aparicio, et al.
Frontiers in Oncology|May 27, 2014
Genetic Modeling of PIM Proteins in Cancer: Proviral Tagging and Cooperation with Oncogenes, Tumor Suppressor Genes, and CarcinogensEnara Aguirre, Oliver Renner, Maja Narlik-Grassow, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|September 25, 2009
Inhibiting PI3K as a therapeutic strategy against cancerLuis Paz-Ares, Carmen Blanco-Aparicio, Rocío García-Carbonero, et al.
Carcinogenesis|March 8, 2007
PTEN, more than the AKT pathwayCarmen Blanco-Aparicio, Oliver Renner, Juan F M Leal, et al.
Cell Cycle (Georgetown, Tex.)|June 15, 2011
Spinophilin loss contributes to tumorigenesis in vivoIrene Ferrer, Sandra Peregrino, Marta Cañamero, et al.
Current Cancer Drug Targets|May 14, 2008
The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implicationsAmancio Carnero, Carmen Blanco-Aparicio, Oliver Renner, et al.
Pageof 7

Showing results (1-10 of 70) with videos related to

Sort By:
Pageof 7
Biochemical Pharmacology|October 9, 2012
Pim kinases in cancer: diagnostic, prognostic and treatment opportunitiesCarmen Blanco-Aparicio, Amancio Carnero
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|October 23, 2008
Genetic modelling of the PTEN/AKT pathway in cancer researchOliver Renner, Carmen Blanco-Aparicio, Amancio Carnero
Medicinal Research Reviews|April 12, 2013
The PIM family of serine/threonine kinases in cancerMaja Narlik-Grassow, Carmen Blanco-Aparicio, Amancio Carnero
The Journal of Biological Chemistry|November 17, 2001
Two clusters of residues at the docking groove of mitogen-activated protein kinases differentially mediate their functional interaction with the tyrosine phosphatases PTP-SL and STEPCéline Tárrega, Carmen Blanco-Aparicio, Juan José Muñoz, et al.
The Biochemical Journal|February 14, 2003
Differential interaction of the tyrosine phosphatases PTP-SL, STEP and HePTP with the mitogen-activated protein kinases ERK1/2 and p38alpha is determined by a kinase specificity sequence and influenced by reducing agentsJuan José Muñoz, Céline Tárrega, Carmen Blanco-Aparicio, et al.
Frontiers in Oncology|May 27, 2014
Genetic Modeling of PIM Proteins in Cancer: Proviral Tagging and Cooperation with Oncogenes, Tumor Suppressor Genes, and CarcinogensEnara Aguirre, Oliver Renner, Maja Narlik-Grassow, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|September 25, 2009
Inhibiting PI3K as a therapeutic strategy against cancerLuis Paz-Ares, Carmen Blanco-Aparicio, Rocío García-Carbonero, et al.
Carcinogenesis|March 8, 2007
PTEN, more than the AKT pathwayCarmen Blanco-Aparicio, Oliver Renner, Juan F M Leal, et al.
Cell Cycle (Georgetown, Tex.)|June 15, 2011
Spinophilin loss contributes to tumorigenesis in vivoIrene Ferrer, Sandra Peregrino, Marta Cañamero, et al.
Current Cancer Drug Targets|May 14, 2008
The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implicationsAmancio Carnero, Carmen Blanco-Aparicio, Oliver Renner, et al.
Pageof 7